Therapy | Trial Name | Proposed # of Patients | Participating Countries | Primary Completion Date |
---|
Remdesivir RCTs | | | | |
---|
Remdesivir | Mild/Moderate 2019-nCoV Remdesivir RCT | 308 | China | April 10, 2020 |
Remdesivir | Severe 2019-nCoV Remdesivir RCT | 453 | China | April 3, 2020 |
Remdesivir | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 600 | US, Hong Kong, South Korea, Singapore, Taiwan | May 1, 2020 |
Remdesivir | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19) | 400 | US, Hong Kong, South Korea, Singapore, Taiwan | May 1, 2020 |
Remdesivir | Adaptive COVID-19 Treatment Trial (ACTT) (NIH supported) | 440 | US, Japan, South Korea, Singapore | April 1, 2023 |
Remdesivir, lopinavir-ritonavir, interferon, hydroxychloroquine | DisCoVeRy: Trial of Treatments for COVID-19 in Hospitalized Adults | 3100 | France | March 1, 2023 |
Lopinavir/Ritonavir RCTs | | | | |
---|
Lopinavir-ritonavir, anakinra, macrolides, corticosteroids, interferon | REMAP-CAP: A randomised, embedded, multi-factorial, adaptive platform trial for community-acquired pneumonia | No maximum | Canada and 13 other countries (Australia, NZ, UK, "a dozen EU countries"), 50 sites | End April/Early May 2020 |
Lopinavir-ritonavir, hydroxychloroquine | Comparison of lopinavir-ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) | 150 | South Korea | May 1, 2020 |
Lopinavir-ritonavir, hydroxychloroquine, remdesivir | CATCO: Canadian Treatments for COVID-19 trial - Canadian Arm of the WHO SOLIDARITY trial | 440 | Canada plus 45 countries so far | March 18, 2022 |
Lopinavir-ritonavir, interferon, Chinese medicine | Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection | 150 | China | January 22, 2021 |
Lopinavir-ritonavir, oseltamivir, arbidol hydrochloride | A Prospective/Retrospective, Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia | 400 | China | June 1, 2020 |
Lopinavir-ritonavir, ribavirin, interferon | Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment | 70 | Hong Kong | January 31, 2022 |
Remdesivir, lopinavir-ritonavir, interferon, hydroxychloroquine | DisCoVeRy: Trial of Treatments for COVID-19 in Hospitalized Adults | 3100 | France, Belgium, German, the Netherlands, Spain, Sweden, UK | March 1, 2023 |
Lopinavir-ritonavir | A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe COVID-19 | 199 | China | February 3, 2020 |
Lopinavir-ritonavir | CORIPREV-LR: COVID-19 Ring-based Prevention Trial With Lopinavir-Ritonavir | 1220 | Canada | March 31, 2021 |
Other Antiviral RCTs | | | | |
---|
Arbidol (antiviral), bromhexine hydrochloride (mucolytic), interferon | Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) | 60 | China | April 15, 2020 |
Darunavir, cobicistat | DACO-nCoV: Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV | 30 | China | August 31, 2020 |
Favipiravir, oseltamivir, protease-inhibitor combinations | THDMS-COVID19: Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID19: A Randomized Control Trial (THDMS-COVID19) | 80 | Thailand | October 31, 2020 |
Investigational Immunotherapy RCTs | | | | |
---|
Lopinavir-ritonavir, anakinra, macrolides, corticosteroids, interferon | REMAP-CAP: A randomised, embedded, multi-factorial, adaptive platform trial for community-acquired pneumonia | No maximum | Canada and 13 other countries (Australia, NZ, UK, "a dozen EU countries"), 50 sites | End April/Early May 2020 |
Bevacizumab | BEST-RCT: Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT | 118 | China | June 30, 2020 |
Emapalumab, anakinra | Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection. | 54 | Italy | July 1, 2020 |
CD24Fc | SAC-COVID: CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment | 230 | US | May 1, 2021 |
Tocilizumab, favipiravir | Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019 | 150 | China | May 1, 2020 |
"PD-1 blocking antibody", thymosin | Immunoregulatory Therapy for 2019-nCoV | 120 | China | April 30, 2020 |
Sarilumab | CORIMUNO-19 - SARI: Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - | 180 | France | March 26, 2021 |
Sarilumab | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 400 | US | March 16, 2021 |
ASC09F, ritonavir, oseltamivir | A Randomized, Open, Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia | 60 | China | May 1, 2020 |
Tocilizumab | COVACTA: A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 330 | US | August 31, 2021 |
Tocilizumab, sarilumab | TOCIVID: Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure | 200 | Denmark | June 1, 2021 |
Human Product RCTs | | | | |
---|
Convalescent plasma | CSSC-OO1: Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19 | 150 | US | December 31, 2022 |
Stem cells | Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia | 48 | China | June 30, 2020 |
Stem cells | Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19) | 90 | China | December 31, 2020 |
Natural-killer cells | NK Cells Treatment for Novel Coronavirus Pneumonia | 30 | China | September 30, 2020 |
Vitamin C RCTs | | | | |
---|
Vitamin C (high-dose IV) | LOVIT: Lessening Organ Dysfunction With VITamin C | 800 | Canada | December 31, 2021 |
Vitamin C (high-dose IV) | Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia | 140 | China | September 30, 2020 |
(Hydroxy)Chloroquine RCTs | | | | |
---|
Chloroquine, azithromycin | ACT COVID19: Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial | 1500 | Canada "+ international" | September 30, 2020 |
Hydroxychloroquine | COVID-19 PEP: Post-Exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2 | 3000 | Canada, US | April 21, 2020 |
Hydroxychloroquine | Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV ) | 30 | China | February 25, 2020 |
Hydroxychloroquine | Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial | 62 | China | February 28, 2020 |
Hydroxychloroquine | Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19) [includes treatment of early symptoms] | 1600 | US | March 1, 2021 |
Hydroxychloroquine, azithromycin | Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II) | 440 | Brazil | August 30, 2020 |
Other RCTs | | | | |
---|
Chinese medicine | Yinhu Qingwen Decoction for the Treatment of Mild/Common CoVID-19 | 300 | China | January 1, 2021 |
Chinese medicine | Yinhu Qingwen Granula for the Treatment of Severe CoVID-19 | 116 | China | March 30, 2021 |
Chinese medicine, N-acetylcysteine (cysteine supplement) | Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu | 136 | China | December 1, 2022 |
Colchicine | COLCORONA: Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) | 6000 | Canada | September 1, 2020 |
Immunoglobulin | The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia | 80 | China | April 30, 2020 |
Interferon, arbidol hydrochloride | A Prospective/Retrospective, Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia | 100 | China | June 1, 2020 |
Losartan | Losartan for Patients With COVID-19 Not Requiring Hospitalization | 516 | US | April 1, 2021 |
Losartan | Losartan for Patients With COVID-19 Requiring Hospitalization | 200 | US | April 1, 2021 |
Methylprednisolone | Steroids-SARI: Glucocorticoid Therapy for Novel Coronavirus Critically Ill Patients With Severe Acute Respiratory Failure | 80 | China | April 25, 2020 |
Methylprednisolone | The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia | 100 | China | June 1, 2020 |
Methylprednisolone | Efficacy and Safety of Corticosteroids in COVID-19 | 400 | China | May 1, 2020 |
Nitric oxide gas | NoCovid: Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 | 240 | US, China, Italy | April 1, 2021 |
Nitric oxide gas | NOSARSCOVID: Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19 | 200 | US, China, Italy | March 21, 2021 |
PUL-042 inhalation solution | PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection | 100 | US | September 1, 2020 |
Tetrandrine | TT-NPC: Tetrandrine Tablets Used in the Treatment of COVID-19 | 60 | China | March 1, 2021 |